trientine has been researched along with Fibrosis in 6 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trientine (TETA), a copper (Cu) chelator, is capable of replenishing Cu in the heart, and Cu repletion reduces cardiac fibrosis in a rodent model of cardiac hypertrophy." | 3.88 | Copper-induced reduction in myocardial fibrosis is associated with increased matrix metalloproteins in a rat model of cardiac hypertrophy. ( Feng, L; Kang, YJ; Liu, J; Liu, Y; Xiao, Y, 2018) |
| "Trientine is a highly selective copper II chelator." | 3.30 | Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy. ( Akhtar, M; Ashkir, Z; Baroja, O; Bedson, E; Clayton, D; Cooper, RM; Dodd, S; Duran, B; Farrant, J; Garratt, C; Harrington, C; Mahmod, M; Miller, CA; Naish, JH; Neubauer, S; Prasad, SK; Raman, B; Reid, A; Schmitt, M; Singh, A; Spowart, C; Valkovič, L; Vaughan, C, 2023) |
| "Some of the implications are that Alzheimer's disease and other diseases of neurodegeneration and fibrotic, inflammatory, and autoimmune diseases may be treatable by lowering the availability of free copper." | 2.44 | The risks of free copper in the body and the development of useful anticopper drugs. ( Brewer, GJ, 2008) |
| "Trientine treatment was safe and tolerated." | 1.72 | Copper chelation in patients with hypertrophic cardiomyopathy. ( Clark, D; Cooper, G; Farrant, JP; Miller, C; Polturi, R; Ray, S; Reid, A; Schmitt, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Reid, A | 2 |
| Miller, C | 1 |
| Farrant, JP | 1 |
| Polturi, R | 1 |
| Clark, D | 1 |
| Ray, S | 1 |
| Cooper, G | 1 |
| Schmitt, M | 2 |
| Farrant, J | 1 |
| Dodd, S | 1 |
| Vaughan, C | 1 |
| Garratt, C | 1 |
| Akhtar, M | 1 |
| Mahmod, M | 1 |
| Neubauer, S | 1 |
| Cooper, RM | 1 |
| Prasad, SK | 1 |
| Singh, A | 1 |
| Valkovič, L | 1 |
| Raman, B | 1 |
| Ashkir, Z | 1 |
| Clayton, D | 1 |
| Baroja, O | 1 |
| Duran, B | 1 |
| Spowart, C | 1 |
| Bedson, E | 1 |
| Naish, JH | 1 |
| Harrington, C | 1 |
| Miller, CA | 1 |
| Liu, Y | 1 |
| Xiao, Y | 1 |
| Liu, J | 1 |
| Feng, L | 1 |
| Kang, YJ | 1 |
| Gong, D | 1 |
| Lu, J | 1 |
| Chen, X | 1 |
| Reddy, S | 1 |
| Crossman, DJ | 1 |
| Glyn-Jones, S | 1 |
| Choong, YS | 1 |
| Kennedy, J | 1 |
| Barry, B | 1 |
| Zhang, S | 1 |
| Chan, YK | 1 |
| Ruggiero, K | 1 |
| Phillips, AR | 1 |
| Cooper, GJ | 1 |
| Brewer, GJ | 2 |
2 reviews available for trientine and Fibrosis
| Article | Year |
|---|---|
The risks of free copper in the body and the development of useful anticopper drugs.
Topics: Alzheimer Disease; Angiogenesis Inhibitors; Autoimmunity; Copper; Fibrosis; Hepatolenticular Degener | 2008 |
Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Topics: Animals; Copper; Fibrosis; Humans; Inflammation; Molybdenum; Neoplasms; Neovascularization, Patholog | 2005 |
1 trial available for trientine and Fibrosis
| Article | Year |
|---|---|
Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Copper; Fibrosis; Heart; Humans; Hypertrophy, Left Ventricular; Trient | 2023 |
3 other studies available for trientine and Fibrosis
| Article | Year |
|---|---|
Copper chelation in patients with hypertrophic cardiomyopathy.
Topics: Biological Availability; Cardiomyopathy, Hypertrophic; Chelating Agents; Copper; Drug Monitoring; Ex | 2022 |
Copper-induced reduction in myocardial fibrosis is associated with increased matrix metalloproteins in a rat model of cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Copper; Disease Models, Animal; Fibrosis; Gene Expression R | 2018 |
A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes.
Topics: Albuminuria; Animals; Chelating Agents; Copper; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2008 |